2.Advances of transforming growth factor-β inhibitors.
Xiao-xiong GE ; Qi-fan ZHOU ; Guo-liang CHEN
Acta Pharmaceutica Sinica 2015;50(4):413-418
Transforming growth factor-β is an important cytokine with various bioactivities, including embryonic development, wound healing, chemotaxis and cell cycle regulation. Epithelial-mesenchymal transition (EMT) is the main pathway of tumor cell to obtain the ability of invasion and metastasis. The TGF-β is the key factor known to induce EMT in cancer cells and plays an important role in the process. In recent years, some progress has been obtained. Some TGF-β inhibitors have approved in the market or in clinical trials. TGF-β inhibitors can play an important role on the treatment of tumors, glaucoma, liver and kidney fibrosis disease and scar repair. Novel TGF-β inhibitors reported in recent years were reviewed in this article.
Epithelial-Mesenchymal Transition
;
Humans
;
Neoplasms
;
Transforming Growth Factor beta
;
antagonists & inhibitors
;
Wound Healing
4.Study on influence of Toxoplasma tachyzoites on human sperm motility parameters in vitro
Yonghua ZHOU ; Hongjie FAN ; Qi GAO ; Ruibin WANG
Chinese Journal of Schistosomiasis Control 1989;0(01):-
Objective To explore the influence of Toxoplasma tachyzoites infection on motility of human spermatozoa in vitro, and explain its possible mechanism. Methods Semen samples obtained from 10 healthy volunteers by masturbation were prepared by the swim-up technique. The samples were then inoculated at 37 ℃ with different concentrations of live Toxoplasma tachyzoites varying among 1?103/ml (Group A), 1?104/ml (Group B), 1?105/ml (Group C), 1?106/ml (Group D), 1?107/ml (Group E) and Group F containing Ham’s F-10 only as the negative control. Motion parameters were analysed by Computer-aided sperm analyzer(CASA) in 0 hour, 1 hour, 2 hours, 4 hours respectively. Modalities of spermatozoa and possible adherence and/or agglutination were observed under the light microscope. Results Distinct adhesion of spermatozoa to Toxoplasma tachyzoites and agglutination were noticed. In all the motion parameters, progressive motility was affected most and dependent upon the incubation time and tachyzoites concentration. Progressive motility showed a significant difference between Group E and the control (P
5.Comparative analysis of radiotherapy and 89Sr radionuclide therapy in the treatment of cervical metastatic cancer pain
Qi YANG ; Jianqiang WANG ; Fan ZHOU ; Xueyuan FAN ; Liqiang ZHONG ; Yuming JIA
Chinese Journal of Biochemical Pharmaceutics 2017;37(9):436-437
Objective To compare the effect of 89Sr radionuclide therapy and radiotherapy in the treatment of metastatic cancer pain of vertebral column. Methods 80 patients with cancer pain of vertebral metastasis in the second People's hospital of Yibin from April 2015 to April 2017, were randomly divided into the control group treated by radiotherapy treatment (n=40) and the the observation group treated by 89Sr radionuclide therapy(n=40), and the effect of treatment were compared between two groups. Results In the observation group, the total effective rate of pain response in patients with metastatic cancer pain of vertebral column was 85.0%, and the control group was 82.5%. There was no significant difference between two groups. The onset time of treatment in the observation group was (6.5±1.7)d, significantly shorter than that of the control group (12.9±2.6)d, and the difference was statistically significance (P<0.05). Conclusion The application of 89Sr radionuclide therapy in the treatment of vertebral metastatic pain is equivalent to the radiotherapy in improving the pain response, but the efficacy could be achieved in a short period of time, so it is worth popularizing widely in clinical practice.
7.Calibrating the working standard for rhG-CSF
Qian JIA ; Xingjun ZHOU ; Xuehong TIAN ; Yuling FAN ; Xiaobo QI ; Zhihua ZHANG
Chinese Journal of Biochemical Pharmaceutics 2001;22(2):81-84
Purpose Both the working standard and corresponding sample(GRAN75)were first calibrated by WHO international standard for G-CSF.Methods MTT method by NFS-60 cells was used. The results were calculated by (4,4)method.Results Three batchs working standards were prepared,two batchs were freeze-dry and the prescription was same as WHO international standard for G-CSF,one batch was injection and the prescription was same as corresponding sample(GRAN75).The biological potency and the FL% of average potency were 3.062×106 、4.276×106IU/ampoule、1.635×107IU/ml and 5.529%、4.291%、4.244% for working standard, and 1.880×107IU/ml and 5.175% for corresponding sample,respectively.Conclusion The working standard which calibrated could be used as working standard in the measurement of rhG-CSF biological activity.
8.Study on determination method of the rhG-CSF biological activity
Qian JIA ; Xingjun ZHOU ; Xuehong TIAN ; Yuling FAN ; Xiaobo QI ; Zhihua ZHANG
Chinese Journal of Biochemical Pharmaceutics 2001;22(1):25-26
Purpose The determination method of rhG-CSF bio logical activity by NFS-60 cells was studied in accordance with WHO internation al standard for G-CSF.Methods MTT method was adopted.R esults The chomosone number of NFS-60 cell was 39, about 1×105 cells/ml to 1×107 cells/ml,the dying color showed gradient when the NFS-60 c ells was dyed by MTT,the method(4,4) was adopted in the determination of rhG-CS F biological activity,the average FL% of potency was 13.560% for single exprimen t,and the CV of inter-assay and intra-assay was lower than 10% and 10.109%,respectively.Conclusion method(4,4) can be us ed in the determination of rhG-CSF biological activity,and the results can guid e the study and the manufacture of rhG-CSF effectively.
9.Study on the Turnover and Treament of Postoperative Residues of Giant Nonfunctioning Pituitary Adenoma with Suprasellar Extension(SSE)
Jianxin WANG ; Songtao QI ; Yuntao LU ; Yuping PENG ; Jun FAN ; Wenke ZHOU
Chinese Journal of Clinical Oncology 2010;37(5):267-270
Objective: To explore the turnover and treament of postoperative remainder of giant nonfunctioning pituitary adenoma with suprasellar extension(SSE). Methods: The clinical data of 68 cases suffering from giant nonfunctioning pituitary adenoma with suprasellar extension(SSE)admitted into our department were retrospectively analyzed.These patients underwent primary transsphenoidal surgery. Results: Twenty cases had SSE adenomas totally removed(20.6%).In other 48 cases(79.34%),SSE residues were shown in MRI recheck at one day after surgery.After 3 months,the 3rd MRI scanning was performed only to find that tumor residues descended to sellar floor in 21 cases,into intrasella in 8 cases,and down to the level of stalk hypophysial and the entrance to the sella in 3 cases.All of Patients with residual tumors received retranssphenoidal resection(the total removal rate of desending SSE residues was 96.9%).There were 2 cases with adenoma residues with slight descending.Obvious SSE adenomas were treated with transtranial approach.The twelve cases with small SSE residues were consecutively observed and two of them received gamma knife treatment because of unobvious postoperative visual improvement.The surgical mortality was 0%.There was no death during follow up in all of these patients.There were no cases with rhinorrhea.meningitis or visual deterioration.Two patients had supradiaphragmatic bleeding detected by routine postoperative CT. Conclusion: Staged surgery with two or multiple transsphenoidal resections is an appropriate treatment for giant nonfunctioning pituitary adenoma with supresellar extension(SSE),with few complications.Futher study is warranted to investigate the growth pattern of pituitary adenoma.
10.The MRP1 expression in childhood acute lymphoblastic leukemia and its clinical significance
Baoling QIU ; Dong WU ; Dan HONG ; Qi ZHOU ; Jun LU ; Junjie FAN ; Jiannong CENG ; Shaoyan HU
Journal of Clinical Pediatrics 2014;(8):745-749
Objective Multidrug resistance-associated protein 1 (MRP1) has been reported with a close correlation with tumor multi-drug resistance. Real-time quantitative PCR (QRT-PCR) was performed to detect the MRP1 gene expression in childhood acute lymphoblastic leukemia (ALL) and its clinical signiifcance was analyzed. Methods Sixty-seven denovo ALL patients and 10 healthier children as bone marrow donor were studied. The chemotherapy was given according to CCLG-2008 protocol. SPSS software was employed to analyze the data and p-value below 0.05 was regarded as statistic signiifcance. Results MRP1 expression level showed a close correlation with ALL risk, the median of MRP1 expression was 4.28 (2.75~6.12), 5.62 (4.99~8.60) and 7.56 (3.66~11.13) for standard-risk group (SR), intermediate-risk group (IR) and high-risk group (HR), respectively. MRP1 mRNA expression in T-ALL group was 7.71 (6.49~14.35), which is higher than that of B-ALL (5.18(3.89~8.46)) (P<0.01). The rate of leukemia cells’ sensitivity to prednisone on 7th day was 70.6%in high expression group (n=34), which was signiifcantly lower than that in low expression group (n=33, 90.9%, P=0.035). The complete remission rateon 33th day was 64.7%in high expression group, and 87.9%in low expression group, which showed a signiifcant difference between them (P=0.026). Conclusions In children ALL, the expression of MRP1 is closely related with immunophenotyping, treatment response, hazard level and disease relapse.